Efficacy and Safety of KI1001 in ≥ 55 Years Old Insomnia Patients

Kuhnil Pharmaceutical

Status and phase

Completed

Phase 3

Conditions

Sleep Initiation and Maintenance Disorders

Treatments

Drug: Placebo KI1001

Drug: KI1001

Study type

Interventional

Funder types

Industry

Identifiers

NCT01450228

10-CC-8302

Details and patient eligibility

About

KI1001(Circadin®, Prolonged release tablet which contains melatonin) has showed its efficacy to improve sleep quality in over 55 years old primary insomnia patients. This is a bridging study to investigate the efficacy and safety of KI1001(Circadin®) in Korean patients.

Full description

Studies throughout the world have shown that insomnia is a common complaint that occurs in 10-50% of the population depending on age, sex and country. Among the wide variety of available treatments of sleep disturbances, the most commonly prescribed hypnotics are the benzodiazepines (BZD) and non-BZD hypnotics.

However, these hypnotics were often associated with rebound, dependency, tolerance, higher risk of falls mainly in the elderly population, anterograde memory disturbances and increased risk for motor accidents the next day.

In response to the unmet clinical need for a safe and efficacious alternative treatment for primary insomnia, that in addition to treating quantitative sleep problems, would improve sleep quality and daytime functioning, a clinical development program on melatonin for the treatment of primary insomnia was initiated.

This study is conducted using a randomised, double-blind, placebo controlled parallel group design, after a single-blind placebo period. Primary insomnia patients aged over 55 will be screened for entry into the study.

After placebo run-in period, Patients will enter a 3 weeks double-blind treatment period.

Primary parameter is quality of sleep, secondary parameters are including getting to sleep, awakening from sleep, behavior following wakefulness, quality of day and night, sleep latency and quality of life.

Enrollment

170 patients

Sex

All

Ages

55+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female and aged ≥55 years
Suffering from primary insomnia according to DSM-IV criteria and for whom this is the consultation complaint
Good anticipated compliance
Written informed consent to participate in the study given by the patient voluntarily
Confirmed diagnosis of primary insomnia by sleep history questionnaire
Established baseline pathology
A good compliance during the two-weeks placebo run-in period defined as 70% to 130% of prescribed tablets
Correct use of the Sleep Diary and of the LSEQ

Exclusion criteria

According to DSM-IV, subjects belonging to the following groups are excluded : 780.59(breathing related sleep disorder); 307.45(circadian thyrhm sleep disorder); 307.47(dyssomnia not otherwise specified); 780.XX(sleep disorder due to a general medical condition)
Known or suspected hypersensitivity to exogenous melatonin or melatonin receptor agonists
Known positive serology for human immunodeficiency virus (HIV) I antibodies or HIV II antibodies
Known chronic active viral hepatitis
Drug abuse or history or drug abuse(including alcohol)
History of severe pathology likely to recur during or immediately after the study
History of severe cardiac disorders
History of severe neurological disorders or cerebral neurosurgery
History of severe psychiatric disorders, especially psychosis and depression, sismotherapy
depression will be assessed by the Raskin scale : a patient with a total score ≥ 6 will not be included
anxiety will be assessed by the Covi scale : a patient with a total score ≥ 6 will not be included
dementia will be assessed with the Mini Mental State (MMS) : a patient with a score ≤ 24 or 26 (depending on the socio-educational level of the patient) will not be included
Neuro-psychiatric pathologies that might interfere with insomnia, patient assessment or study medication
Use of psychotropic treatments for the past 3 months and during the study
Use of benzodiazepines or other hypnotics during preceding two weeks (including all benzodiazepines; zopiclone, zolpidem, zaleplon, barbiturates, buspirone and hydroxyzine)
All hypnotics or treatments used as an hypnotic are not allowed during the study
Severe pain likely to interfere with sleep
Other sleep disorders according to DSM-IV criteria identified by numerical ICD 9 code: breathing-related sleep disorder (780.59), circadian rhythm sleep disorder (307.45), dyssomnia not otherwise specified (307.47) and other sleep disorders (780.xx)
Serious diseases that could interfere with patient assessment
Organic pathologies which have not stabilised and that might interfere with sleep, patient assessment or study medication
Intercurrent acute or chronic somatic diseases likely to interact with sleep (for example: chronic pain from any aetiology, benign prostatic hypertrophy likely to require surgery in the coming six months)
Any concomitant documented progressive disease likely to interfere with the conduct of the study
Any medical condition which might interfere with the completion of the study, or which would be adversely affected and thereby increasing the risk for the patient or interfering with patient assessments.
Patients with an excessive consumption of alcohol, coffee or tea
Patients with an irregular lifestyle or life pattern (e.g. shift workers and patients likely to be jet lagged)
Patients with a Body Mass Index above 30 - obesity
Patients who have taken any investigational drug within two months preceding the first dose of the study drug. Investigational drug is defined as any drug for which a marketing authorisation has not been granted in the country where the study was conducted.
Patients receiving concomitant treatment which are not permitted
A positive drug screen (benzodiazepines and opiates) during the initial two week placebo run-in period